Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111800
Status:
COMPLETED
Last Update Posted:
2018-03-21
First Post:
2005-05-25
Brief Title:
A New Oral Treatment For Type II Diabetes Mellitus
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A 12-Week Parallel-Group Double-Blind Randomized Placebo-Controlled Multicenter Dose Ranging Study to Evaluate the Efficacy Safety and Tolerability of Denagliptin Administered Orally Once Daily as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus
Detailed Description:
A 12-Week Parallel-Group Double-Blind Randomized Placebo-Controlled Multicenter Dose Ranging Study to Evaluate the Efficacy Safety and Tolerability of GW823093 Administered Orally Once Daily as Monotherapy in Subjects With Type 2 Diabetes Mellitus followed by a 12-week Active Treatment Extension
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None